{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T17:10:59Z","timestamp":1783012259500,"version":"3.54.6"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism Open"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.metop.2021.100142","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T05:18:18Z","timestamp":1634879898000},"page":"100142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Real world evidence: Patients with refractory pemphigus treated with Rituximab"],"prefix":"10.1016","volume":"12","author":[{"given":"Vagiani","family":"Perifani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Dalamaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Theodoropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9076-3866","authenticated-orcid":false,"given":"Sofia","family":"Theotokoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Syrmali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Loumou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Papadavid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metop.2021.100142_bib1","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.clindermatol.2011.01.013","article-title":"Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis)","volume":"29","author":"Joly","year":"2011","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.metop.2021.100142_bib2","first-page":"844","article-title":"Autoimmune bullous skin diseases. Part 1: clinical manifestations","volume":"9","author":"Kneisel","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.metop.2021.100142_bib3","first-page":"927","article-title":"Autoimmune bullous skin diseases. Part 2: diagnosis and therapy","volume":"9","author":"Kneisel","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.metop.2021.100142_bib4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/jdv.12772","article-title":"S2 guideline for diagnosis and treatment--guided by the European dermatology forum (EDF) in cooperation with the European academy of dermatology and Venereology (EADV)","volume":"29","author":"Hertl","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.metop.2021.100142_bib5","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/0092-8674(91)90360-B","article-title":"Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion","volume":"67","author":"Amagai","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.metop.2021.100142_bib6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.intimp.2017.11.005","article-title":"Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review","volume":"54","author":"Tavakolpour","year":"2018","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.metop.2021.100142_bib7","first-page":"e1173","article-title":"Anti-interleukin and associated receptors monoclonal antibodies therapy in autoimmune diseases","volume":"3","author":"Tavakolpour","year":"2016","journal-title":"Receptors Clin Investig"},{"issue":"5 Suppl 14","key":"10.1016\/j.metop.2021.100142_bib8","first-page":"66","article-title":"Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma","volume":"26","author":"Grillo-L\u00f3pez","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.metop.2021.100142_bib9","first-page":"325","article-title":"Targeted therapies in rheumatoid arthritis: focus on rituximab","volume":"1","author":"Teng","year":"2007","journal-title":"Biologics"},{"key":"10.1016\/j.metop.2021.100142_bib10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000357031","article-title":"Pilot study of 19 patients with severe pemphigus: prophylactic treatment with rituximab does not appear to be beneficial","volume":"228","author":"Gregoriou","year":"2014","journal-title":"Dermatology"},{"key":"10.1016\/j.metop.2021.100142_bib11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/bjd.14405","article-title":"Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus","volume":"175","author":"Boulard","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.metop.2021.100142_bib12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jaad.2011.11.007","article-title":"Therapy with rituximab for autoimmune pemphigus: results from a single-centre observational study on 42 cases with long-term follow-up","volume":"67","author":"G1","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.metop.2021.100142_bib13","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jaad.2010.07.032","article-title":"Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients","volume":"65","author":"Kasperkiewicz","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.metop.2021.100142_bib14","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/1346-8138.13757","article-title":"Adjuvant rituximab treatment for pemphigus: a retrospective study of 45 patients at a single center with long-term follow up","volume":"44","author":"Kim","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.metop.2021.100142_bib15","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/archderm.143.8.1033","article-title":"Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature","volume":"143","author":"Cianchini","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.metop.2021.100142_bib16","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/ijd.13400","article-title":"Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey","volume":"55","author":"Uzun","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.metop.2021.100142_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198074","article-title":"Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: a retrospective analysis","volume":"13","author":"Agarwal","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.metop.2021.100142_bib18","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1067\/mjd.2002.126273","article-title":"Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder","volume":"47","author":"Salopek","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.metop.2021.100142_bib19","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1365-4632.2012.5847.x","article-title":"Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial","volume":"52","author":"Balighi","year":"2013","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.metop.2021.100142_bib20","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jdv.12080","article-title":"Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities","volume":"28","author":"Cho","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.metop.2021.100142_bib21","first-page":"727","article-title":"Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases","volume":"10","author":"Kasperkiewicz","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.metop.2021.100142_bib22","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1365-2133.2011.10411.x","article-title":"Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients","volume":"165","author":"Kim","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.metop.2021.100142_bib23","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archdermatol.2012.1522","article-title":"Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients","volume":"148","author":"Lunardon","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.metop.2021.100142_bib24","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jaad.2011.12.019","article-title":"Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up","volume":"67","author":"Reguiai","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.metop.2021.100142_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-012-0017-3","article-title":"Rituximab in the therapy of pemphigus vulgaris","volume":"2","author":"Zakka","year":"2012","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.metop.2021.100142_bib26","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/jdv.12678","article-title":"An assessment of therapy history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab","volume":"29","author":"Amber","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.metop.2021.100142_bib27","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.metop.2021.100142_bib28","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/j.jaad.2020.04.005","article-title":"Treatment considerations for patients with pemphigus during the COVID-19 pandemic","volume":"82","author":"Shakshouk","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.metop.2021.100142_bib29","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1111\/jdv.16525","article-title":"Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic","volume":"34","author":"Kasperkiewicz","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Metabolism Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589936821000669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589936821000669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:57:09Z","timestamp":1762905429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589936821000669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":29,"alternative-id":["S2589936821000669"],"URL":"https:\/\/doi.org\/10.1016\/j.metop.2021.100142","relation":{},"ISSN":["2589-9368"],"issn-type":[{"value":"2589-9368","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real world evidence: Patients with refractory pemphigus treated with Rituximab","name":"articletitle","label":"Article Title"},{"value":"Metabolism Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metop.2021.100142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100142"}}